HC Wainwright Has Negative View of Urogen Pharma Q2 Earnings

Urogen Pharma (NASDAQ:URGN) – Stock analysts at HC Wainwright dropped their Q2 2025 EPS estimates for shares of Urogen Pharma in a research note issued on Monday, June 16th. HC Wainwright analyst R. Selvaraju now forecasts that the company will post earnings per share of ($0.80) for the quarter, down from their prior estimate of ($0.74). HC Wainwright has a “Buy” rating and a $50.00 price target on the stock. The consensus estimate for Urogen Pharma’s current full-year earnings is ($3.12) per share. HC Wainwright also issued estimates for Urogen Pharma’s Q3 2025 earnings at ($0.69) EPS, Q4 2025 earnings at ($0.69) EPS, FY2025 earnings at ($3.10) EPS, Q1 2026 earnings at ($0.56) EPS, Q2 2026 earnings at ($0.15) EPS, Q3 2026 earnings at $0.02 EPS, Q4 2026 earnings at $0.26 EPS and FY2026 earnings at $0.43 EPS.

Several other brokerages have also recently issued reports on URGN. D. Boral Capital reaffirmed a “buy” rating and set a $25.00 target price on shares of Urogen Pharma in a research note on Thursday, June 12th. Oppenheimer set a $31.00 price target on shares of Urogen Pharma and gave the stock a “buy” rating in a research note on Friday, June 13th. Scotiabank reaffirmed an “outperform” rating on shares of Urogen Pharma in a research note on Friday, June 13th. The Goldman Sachs Group set a $16.00 price objective on shares of Urogen Pharma and gave the company a “neutral” rating in a report on Friday, June 13th. Finally, Guggenheim restated a “buy” rating and set a $30.00 target price (up from $15.00) on shares of Urogen Pharma in a report on Friday, June 13th. One analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $32.86.

Urogen Pharma Stock Up 12.3%

NASDAQ URGN opened at $14.87 on Wednesday. The business has a fifty day moving average price of $8.90 and a 200 day moving average price of $10.12. Urogen Pharma has a one year low of $3.42 and a one year high of $18.15. The company has a debt-to-equity ratio of 4.77, a quick ratio of 5.47 and a current ratio of 5.65. The company has a market cap of $685.66 million, a P/E ratio of -4.68 and a beta of 0.40.

Urogen Pharma (NASDAQ:URGN) last announced its earnings results on Monday, May 12th. The company reported ($0.92) EPS for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.09). The firm had revenue of $20.25 million for the quarter, compared to analyst estimates of $22.71 million. Urogen Pharma had a negative net margin of 150.68% and a negative return on equity of 97,487.15%.

Institutional Investors Weigh In On Urogen Pharma

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its stake in shares of Urogen Pharma by 4.7% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,667 shares of the company’s stock valued at $231,000 after purchasing an additional 969 shares during the last quarter. Wellington Management Group LLP increased its position in shares of Urogen Pharma by 0.8% during the first quarter. Wellington Management Group LLP now owns 148,078 shares of the company’s stock valued at $1,638,000 after acquiring an additional 1,125 shares during the last quarter. Rhumbline Advisers increased its position in shares of Urogen Pharma by 2.8% during the fourth quarter. Rhumbline Advisers now owns 51,270 shares of the company’s stock valued at $546,000 after acquiring an additional 1,402 shares during the last quarter. MetLife Investment Management LLC raised its stake in shares of Urogen Pharma by 13.6% in the 4th quarter. MetLife Investment Management LLC now owns 22,766 shares of the company’s stock valued at $242,000 after acquiring an additional 2,727 shares during the period. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of Urogen Pharma by 3.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 93,517 shares of the company’s stock worth $996,000 after acquiring an additional 3,024 shares during the last quarter. Institutional investors and hedge funds own 91.29% of the company’s stock.

Insider Activity

In related news, insider Mark Schoenberg sold 5,162 shares of the company’s stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $7.37, for a total value of $38,043.94. Following the transaction, the insider now directly owns 153,378 shares in the company, valued at approximately $1,130,395.86. This represents a 3.26% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 5.10% of the company’s stock.

Urogen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.